116816 | Adenosine 3ʹ,5ʹ-cyclic Monophosphorothioate, 8-Bromo-, Rp-Isomer, Sodium Salt - Calbiochem

116816
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical Formula
      C₁₀H₁₀BrN₅O₅PS · Na

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      116816-5UMOL
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 5 umol
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA potent, cell-permeable, and reversible metabolically-stable cAMP antagonist that inhibits cAMP-dependent protein kinase and shows preference for PKA type I. More lipophilic than cAMP antagonist Rp-cAMPS (Cat. No. 116814).
          Note: 5 µmol = 2.23 mg.
          Catalogue Number116816
          Brand Family Calbiochem®
          SynonymsRp-8-Br-cAMPS, Na, PKA Inhibitor VI
          References
          ReferencesCalaghan, S.C., et al. 1999. Pflugers Arch. 437, 780.
          Gjertsen, B.T., et al. 1995. J. Biol. Chem. 270, 20599.
          Yokozaki, H., et al. 1992. Cancer Res. 52, 2504.
          Dostmann, W.R. et al. 1990. J. Biol. Chem. 265, 10484.
          Product Information
          ATP CompetitiveN
          DeclarationSold under license of Patent DE 3,802,865.4 issued to BIOLOG LSI.
          FormLyophilized
          Hill FormulaC₁₀H₁₀BrN₅O₅PS · Na
          Chemical formulaC₁₀H₁₀BrN₅O₅PS · Na
          Hygroscopic Hygroscopic
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetPKA 1
          Purity≥99% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          116816

          References

          Reference overview
          Calaghan, S.C., et al. 1999. Pflugers Arch. 437, 780.
          Gjertsen, B.T., et al. 1995. J. Biol. Chem. 270, 20599.
          Yokozaki, H., et al. 1992. Cancer Res. 52, 2504.
          Dostmann, W.R. et al. 1990. J. Biol. Chem. 265, 10484.

          Brochure

          Title
          Inhibitor Sourcebook 3rd Edition, EMD

          Citations

          Title
        • Ralf Gutzmer, et al. (2005) Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. Journal of Immunology 5224-5232.
        • Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision08-January-2010 RFH
          SynonymsRp-8-Br-cAMPS, Na, PKA Inhibitor VI
          DescriptionCell-permeable, potent, reversible, and metabolically stable antagonist of cAMP that is resistant to the action of mammalian cyclic nucleotide phosphodiesterases. Rp-8-Br-cAMPS is more lipophilic as compared to 8-Br-cAMP and Rp-cAMPS. In contrast to other common ATP-site inhibitors or to its parent compound Rp-cAMPS, Rp-8-Br-cAMPS discriminates between both isozymes of protein kinase A, preferring type I, thus providing additional selectivity. By occupying cAMP binding sites, prevents dissociation and activation of the kinase holoenzyme. λ = 264 nm (H2O, pH 7.0); εmax 17,000 M-1cm-1.
          FormLyophilized
          Chemical formulaC₁₀H₁₀BrN₅O₅PS · Na
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityH₂O (40 mg/ml)
          Storage -20°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesCalaghan, S.C., et al. 1999. Pflugers Arch. 437, 780.
          Gjertsen, B.T., et al. 1995. J. Biol. Chem. 270, 20599.
          Yokozaki, H., et al. 1992. Cancer Res. 52, 2504.
          Dostmann, W.R. et al. 1990. J. Biol. Chem. 265, 10484.
          Citation
        • Ralf Gutzmer, et al. (2005) Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. Journal of Immunology 5224-5232.